Home › Crohn's Disease › New York
Crohn's Disease clinical trials in New York
36 studies for Crohn's Disease are looking for participants at sites in New York.
Cities in New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- New York Gastroenterology Associates ( Site 0253), New York
RecruitingPhase 3
All ages · All sexes · Updated Oct 2, 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Northwell Health Physician Partners Center for Advanced IBD Care ( Site 5017), Great Neck
- NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
- Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
- and 2 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Westchester Putnam Gastroenterology PC, Carmel
- Five Towns Gastroenterology, Cedarhurst
- IMIDeology, Elmhurst
- and 5 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 25, 2026 · NCT05923073Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Nyu Langone Long Island Clinical Research Associates - Lake Success /ID# 265566, Lake Success
- Northwell Health-Lenox Hill Hospital /ID# 265527, New York
- Care Access - Yonkers /ID# 266781, Yonkers
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Westchester Putnam Gastroenterology, Carmel
- New York Gastroenterology Associates, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Westchester Putnam Gastroenterology, Carmel
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Weill Cornell Medical College, New York
- and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
- Rochester Clinical Research, Inc, Rochester
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- New York Gastroenterology Associates, New York
- Care Access - Yonkers, Yonkers
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- MedTraits NY-Site Number: 8400045, Maspeth
- Manhattan Clinical Research, LLC-Site Number: 8400069, New York
- NYU Langone Health-Site Number: 8400091, New York
- and 4 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- MedTraits NY-Site Number: 8400045, Maspeth
- NYU Langone Health-Site Number: 8400091, New York
- Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Icahn School of Medicine at Mount Sinai /ID# 254880, New York
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- NYU Langone Health, New York
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Standardized Microbiota Transplant Therapy in Crohn's Disease
- NYU Langone Health, New York
RecruitingPhase 2
Ages 18 to 89 · All sexes · Updated Sep 8, 2026 · NCT06631586A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- New York Gastroenterology Associates, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
- Weill Cornell Medicine, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06274554Behavioral Therapy for Crohn's Disease
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
Recruiting
Ages 18 to 65 · All sexes · Updated Aug 12, 2026 · NCT06512597Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Saratoga Schenectady Gastroenterology Associates, Burnt Hills
- NYU Langone Health, New York
- Cornell University, New York
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- New York University, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516Low Dose IL-2 for the Treatment of Crohn's Disease
- Mount Sinai, New York
RecruitingPhase 1/2
Ages 12 to 80 · All sexes · Updated Aug 3, 2026 · NCT04263831Autologous Stem Cell Transplant for Crohn's Disease
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT03219359Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Icahn School of Medicine at Mount Sinai /ID# 262216, New York
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- New York Presbyterian Hospital, New York
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jun 5, 2026 · NCT06976853Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cohen Children's Medical Center of NY, Lake Success
- Columbia University Medical Center, New York
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Columbia University Medical Center, New York-Presbyterian Hospital, New York
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated May 27, 2026 · NCT06227910Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
- Weill Cornell Medical College, New York
Recruiting
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT03256240A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- The Steven and Alexandra Cohen Childrens Medical Center of New York - BRANY - PPDS, New Hyde Park
- Stony Brook University Medical Center, Stony Brook
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, New York
- Mirador Therapeutics Selected Site, Rochester
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
- Icahn School of Medicine at Mount Sinai, New York
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06001450Treatment of Moderate to Severe Refractory Crohn's Disease
- Mount Sinai Health Systems, New York
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962Helmsley 3.0: Abbreviated MRE
- NYU Langone, New York
RecruitingObservational study
Ages 10 and older · All sexes · Updated Oct 27, 2025 · NCT06533228From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.